Profile data is unavailable for this security.
About the company
Stella Pharma Corp is a Japan-based company mainly engaged in the therapeutic drug research and development. It is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
- Revenue in JPY (TTM)284.89m
- Net income in JPY-726.61m
- Incorporated2007
- Employees44.00
- LocationStella Pharma Corp3-2-7, Koraibashi, Chuo-kuOSAKA-SHI 541-0043JapanJPN
- Phone+81 647071516
- Fax+81 647072077
- Websitehttps://stella-pharma.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 8.92bn | 159.00 | -- | 1.69 | -- | -- | -- | -- | -- | 1,032.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.73 | -- | 0.2846 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| Solasia Pharma KK | 95.00m | -1.21bn | 9.60bn | 24.00 | -- | 4.34 | -- | 101.05 | -6.62 | -6.62 | 0.51 | 10.14 | 0.0408 | 0.5763 | 0.7724 | 3,958,333.00 | -52.22 | -48.57 | -57.64 | -58.83 | 10.53 | 71.01 | -1,278.95 | -300.89 | 7.39 | -- | 0.016 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| Perseus Proteomics Inc | 108.86m | -966.41m | 9.77bn | 25.00 | -- | 5.32 | -- | 89.78 | -75.66 | -75.66 | 8.50 | 124.71 | 0.0521 | 2.76 | 9.44 | 4,354,200.00 | -46.23 | -41.34 | -48.96 | -43.43 | 89.12 | 91.72 | -887.79 | -891.26 | 15.69 | -101.42 | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| RaQualia Pharma Inc | 2.30bn | -673.00m | 10.08bn | 67.00 | -- | 1.79 | -- | 4.39 | -31.12 | -31.12 | 106.28 | 261.02 | 0.2652 | 3.82 | 2.89 | 34,300,980.00 | -7.77 | 2.13 | -8.56 | 2.26 | 84.78 | 88.49 | -29.28 | 5.32 | 3.55 | -- | 0.3972 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| ReproCell Inc | 2.60bn | -196.44m | 10.94bn | 96.00 | -- | 1.25 | -- | 4.21 | -2.21 | -2.21 | 29.29 | 92.79 | 0.2916 | 5.05 | 7.43 | 27,084,280.00 | -2.20 | -7.35 | -2.37 | -8.00 | 51.10 | 39.83 | -7.55 | -27.16 | 8.97 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Symbio Pharmaceuticals Ltd | 3.07bn | -4.02bn | 11.11bn | 109.00 | -- | 2.15 | -- | 3.62 | -92.13 | -92.13 | 70.03 | 112.55 | 0.4225 | 2.97 | 4.47 | 28,137,370.00 | -55.36 | -19.18 | -62.58 | -23.62 | 77.57 | 65.84 | -131.05 | -24.32 | 6.51 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Ohki Healthcare Holdings Co Ltd | 342.45bn | 1.87bn | 12.00bn | 632.00 | 6.26 | 0.3897 | 5.48 | 0.035 | 136.22 | 136.22 | 24,995.05 | 2,189.15 | 2.45 | 12.90 | 4.52 | 541,849,700.00 | 1.29 | 1.85 | 5.54 | 8.42 | 5.00 | 6.16 | 0.5268 | 0.7178 | 0.8641 | -- | 0.2547 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
| Oncolys Biopharma Inc | 31.38m | -1.91bn | 15.88bn | 34.00 | -- | 7.36 | -- | 505.85 | -94.41 | -94.41 | 1.53 | 86.36 | 0.015 | 0.00 | 0.2917 | 923,058.80 | -91.65 | -45.75 | -104.28 | -51.86 | 0.00 | 60.46 | -6,093.40 | -233.66 | 9.72 | -102.93 | 0.1442 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.31bn | 16.25bn | 11.00 | -- | 5.07 | -- | -- | -72.79 | -72.79 | 0.00 | 167.60 | 0.00 | -- | -- | 0.00 | -38.05 | -62.25 | -42.35 | -70.91 | -- | -- | -- | -2,015.62 | -- | -- | -- | -- | -- | -- | 2.77 | -- | -- | -- |
| Stella Pharma Corp | 284.89m | -726.61m | 16.88bn | 44.00 | -- | 5.48 | -- | 59.25 | -22.94 | -22.94 | 8.91 | 90.49 | 0.061 | 0.0433 | 2.59 | 6,474,773.00 | -15.55 | -22.50 | -16.34 | -24.83 | 84.75 | -- | -255.05 | -488.65 | 17.82 | -563.58 | 0.217 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
| TAIKO PHARMACEUTICAL CO LTD | 6.28bn | -2.34bn | 18.38bn | 208.00 | -- | 2.26 | -- | 2.93 | -46.93 | -46.93 | 125.40 | 160.66 | 0.434 | 1.69 | 2.94 | 30,201,920.00 | -16.12 | -- | -19.68 | -- | 55.73 | -- | -37.15 | -- | 2.83 | -- | 0.2166 | -- | 21.43 | -- | 26.23 | -- | -- | -- |
| CellSeed Inc | 199.47m | -957.04m | 19.58bn | 35.00 | -- | 8.93 | -- | 98.16 | -30.72 | -30.72 | 6.40 | 63.29 | 0.0892 | 1.65 | 7.91 | 5,699,172.00 | -42.79 | -49.69 | -46.02 | -54.55 | 55.38 | 63.66 | -479.79 | -428.62 | 16.42 | -5,460.76 | 0.0651 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
| Astena Holdings Co Ltd | 53.39bn | 2.09bn | 20.25bn | 1.40k | 9.39 | 0.6851 | 4.40 | 0.3792 | 52.62 | 52.62 | 1,341.82 | 721.11 | 0.7976 | 3.29 | 2.69 | 38,024,920.00 | 3.12 | 2.49 | 5.76 | 4.44 | 34.11 | 25.33 | 3.91 | 2.32 | 0.879 | 391.65 | 0.349 | 44.92 | 4.73 | -2.85 | 100.61 | -3.85 | 38.54 | 11.38 |
| StemRIM Inc | 0.00 | -2.02bn | 21.96bn | 44.00 | -- | 2.47 | -- | -- | -32.98 | -32.98 | 0.00 | 144.57 | 0.00 | -- | -- | 0.00 | -20.44 | -8.34 | -20.74 | -8.49 | -- | -- | -- | -68.74 | 131.03 | -11,344.72 | 0.00 | -- | -100.00 | -- | -1,301.17 | -- | -4.35 | -- |
| Fuso Pharmaceutical Industries Ltd | 57.72bn | 2.20bn | 24.64bn | 1.31k | 10.13 | 0.5876 | 5.50 | 0.4269 | 257.39 | 257.39 | 6,774.96 | 4,436.49 | 0.7581 | 3.07 | 2.33 | 44,163,730.00 | 2.89 | 1.91 | 4.97 | 3.09 | 26.58 | 26.92 | 3.81 | 2.69 | 0.9406 | 50.75 | 0.267 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
Data as of Nov 22 2024. Currency figures normalised to Stella Pharma Corp's reporting currency: Japanese Yen JPY
9.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nikko Asset Management Co., Ltd.as of 27 Sep 2023 | 3.11m | 9.14% |
| Simplex Asset Management Co., Ltd.as of 07 Nov 2024 | 111.80k | 0.33% |
Data from 30 Sep 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
